On the 29th of May, I’ve explained from a pharmacovigilant point of view why remdesivir is least likely to be considered as a safe treatment for COVID-19 patients and I wish to add some other pieces of evidence not mentioned in that rapid response [1].

References

1. Kelleni M. “Rapid Response: Remdesivir is least likely to be effective for safe treatment of COVID-19: A pharmacovigilant point of view”. British Medical Journal 369 (2020): m2097.
2. Nasir M., et al. “Use of Remdesivir in the Management of COVID-19: A Systematic Review on Current Evidences”. Mymensingh Medical Journal 2 (2020): 481-487.
3. Wang Y., et al. “Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial”. Lancet (London, England)10236 (2020): 1569-1578.
4. “Compassionate Use of Remdesivir in Covid-19”. New England Journal of Medicine25 (2020): e101.
5. Yoo JH. “Uncertainty about the Efficacy of Remdesivir on COVID-19”. Journal of Korean Medical Science23 (2020): e221.

Citation

Citation: Mina T Kelleni. “Remdesivir-Gate for COVID-19”. Acta Scientific Gastrointestinal Disorders 3.8 (2020): 01.

Copyright

Copyright: © 2020 Mina T Kelleni. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.